Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.29EUR
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
€75.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,507,244
52-wk High
€84.82
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €94,535.77
Shares Outstanding(Mil.): 1,251.63
Dividend: 3.03
Yield (%): 4.01

Financials

  SASY.PA Industry Sector
P/E (TTM): 29.36 29.75 32.14
EPS (TTM): 2.57 -- --
ROI: 3.63 13.18 12.83
ROE: 5.70 15.14 14.95

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

Oct 04 2018

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

Oct 04 2018

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

UPDATE 1-Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

Sanofi must face trial over claim it breached licensing deal - judge

French drugmaker Sanofi must face a claim by Illinois-based Elorac Pharmaceuticals that it breached a contract to commercialize the latter's osteoarthritis cream Zuacta in Canada, a federal judge has ruled.

Sep 24 2018

Bayer hemophilia treatment wins thumbs-up from EU panel

Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.

Sep 21 2018

Sanofi pledges to keep up its restructuring efforts

(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)

Sep 18 2018

REFILE-UPDATE 1-Sanofi pledges to keep up its restructuring efforts

PARIS, Sept 14 Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well.

Sep 18 2018

Sanofi pledges to keep up restructuring efforts

PARIS, Sept 14 Sanofi said it would continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations.

Sep 14 2018

Earnings vs. Estimates